Balzarini, J. Metabolism and mechanism of antiretroviral action of purine and pyrimidine deriva- tives. Pharm. World Sci. 1994, 16, 113-126; b) De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discovery 2002, 1, 13-25....
It is well tolerated and, due to its mechanism of action, is likely to be active against viruses resistant to other class of antiretroviral drugs, such as nucleosides, nucleotides and non nucleosides reverse transcriptase inhibitors, protease and entry inhibitors. However as with other antivirals, ...
The Food and Drug Administration (FDA) has licensed many antiretroviral medications to treat human immunodeficiency virus type 1 (HIV-1), however, treatment options for people with multi-drug resistant HIV remain limited. Medication resistance, undesirable effects, prior tolerance, and previous interlace...
It is recommended only for use in combination antiretroviral regimens for highly treatmentexperienced patients or those infected with HIV-1 strains resistant to multiple protease inhibitors and susceptible to tipranavir. Mechanism of action Like other HIV protease inhibitors, tipranavir binds to the ...
Mechanism of Action Gag-Pol polyprotein Modulator Integrase (Human immunodeficiency virus 1) Inhibitor Identification Summary Dolutegravir is an antiviral agent used for the treatment of HIV-1 infections in combination with other antiretroviral agents. Brand Names Dovato, Juluca, Tivicay, Triumeq Generic ...
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action In patients infected by HIV, the efficacy of highly active antiretroviral (ARV) therapy through the blockade of different steps of the retrovirus life cycl... Caroline,Bazzoli,Vincent,...
Rilpivirine in combination with cabotegravir is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents - ≥12 years old and weighing at least 35kg - to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 ...
E_cacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1 infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase IIb trial J Acquir Immune Defic Syndr, 62 (2) (2013), pp. 171-179, 10....
Molecular Mechanism of Potent Capsid-Targeting Antiretroviral Drugsdoi:10.1016/j.bpj.2018.11.118Sruthi MurlidaranJuan R. PerillaBiophysical Journal
HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality PLoS Pathog., 10 (2014), Article e1004078 CrossrefView in ScopusGoogle Scholar [61] ...